E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-κB modulation

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Ren, Zijia ^a,b   Kang, Wenyao ^a,b   Wang, Lihua ^c   Sun, Baoliang ^d   Ma, Jiajia ^a,b   Zheng, Chaogu ^a,b   Sun, Jie ^a,b   Tian, Zhigang ^a,b   Yang, Xiaoyi ^d   Xiao, Weihua ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

E2F1; ICAM 1; NF B; Short hairpin RNA; Tumor immunity

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR RELA; E2F1 PROTEIN, HUMAN; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR IMMUNITY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; APOPTOSIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HELA CELL LINE; IMMUNOLOGY; INNATE IMMUNITY; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR;

ANIMALS; APOPTOSIS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; I-KAPPA B PROTEINS; IMMUNITY, INNATE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899643243     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-84     Document Type: Article

References (30)

1. Croci DO, Salatino M. Tumor immune escape mechanisms that operate during metastasis. Curr Pharm Biotechnol 2011, 12:1923-1936. 10.2174/138920111798376987, 21470132.
2. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002, 71:907-920.
3. Zamai L, Rana R, Mazzotti G, Centurione L, Di Pietro R, Vitale M. Lymphocyte binding to K562 cells: effect of target cell irradiation and correlation with ICAM-1 and LFA-3 expression. Eur J Histochem 1994, 38(Suppl 1):53-60.
4. Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells; implications for the intratumoral vaccine therapy. Cancer Gene Ther 2004, 11:665-680. 10.1038/sj.cgt.7700741, 15354200.
5. Uzendoski K, Kantor JA, Abrams SI, Schlom J, Hodge JW. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997, 8:851-860. 10.1089/hum.1997.8.7-851, 9143911.
6. Koyama S. Immunosuppressive effect of shedding intercellular adhesion molecule 1 antigen on cell-mediated cytotoxicity against tumor cells. Jpn J Cancer Res 1994, 85:131-134. 10.1111/j.1349-7006.1994.tb02072.x, 7908284.
7. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, Denissenko MF. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005, 26:943-950.
8. Simmons DL. The role of ICAM expression in immunity and disease. Cancer Surv 1995, 24:141-155.
9. Wolfram RM, Budinsky AC, Brodowicz T, Kubista M, Köstler WJ, Kichler-Lakomy C, Hellan M, Kahlhammer G, Wiltschke C, Zielinski CC. Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 2000, 88:239-244. 10.1002/1097-0215(20001015)88:2<239::AID-IJC15>3.0.CO;2-Z, 11004675.
10. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993, 365:349-352. 10.1038/365349a0, 8377827.
11. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 2006, 66:11897-11906. 10.1158/0008-5472.CAN-06-2497, 17178887.
12. Zheng C, Ren Z, Wang H, Zhang W, Kalvakolanu DV, Tian Z, Xiao W. E2F1 induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells. Cancer Res 2009, 69:2324-2331. 10.1158/0008-5472.CAN-08-4113, 19276347.
13. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203-209. 10.1016/S1535-6108(02)00030-2, 12086878.
14. Hou J, Baichwal V, Cao Z. Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1994, 91:11641-11645. 10.1073/pnas.91.24.11641, 45287, 7972116.
15. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995, 270:933-943. 10.1074/jbc.270.2.933, 7822333.
16. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999, 66:876-888.
17. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998, 95:749-758. 10.1016/S0092-8674(00)81698-0, 9865693.
18. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000, 14:804-816. 316494, 10766737.
19. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990, 144:4579-4586.
20. Chong AS, Boussy IA, Jiang XL, Lamas M, Graf LH. CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol 1994, 157:92-105. 10.1006/cimm.1994.1208, 7518755.
21. Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD. Cytokine-induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 2006, 119:1377-1382. 10.1002/ijc.21994, 16642465.
22. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
23. Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3 + CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310. 10.1182/blood-2011-02-336321, 21821703.
24. Lim CA, Yao F, Wong JJ, George J, Xu H, Chiu KP, Sung WK, Lipovich L, Vega VB, Chen J, Shahab A, Zhao XD, Hibberd M, Wei CL, Lim B, Ng HH, Ruan Y, Chin KC. Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB upon TLR4 activation. Mol Cell 2007, 27:622-635.
25. Tachimori A, Yamada N, Sakate Y, Yashiro M, Maeda K, Ohira M, Nishino H, Hirakawa K. Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma. Eur J Cancer 2005, 41:1802-1810. 10.1016/j.ejca.2005.04.036, 16051479.
26. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 2011, 236:567-579. 10.1258/ebm.2011.011007, 3229261, 21486861.
27. Roland CL, Dineen SP, Toombs JE, Carbon JG, Smith CW, Brekken RA, Barnett CC. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood) 2010, 235:263-270. 10.1258/ebm.2009.009215, 20404043.
28. Vesalainen S, Lipponen P, Talja M, Syrjänen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994, 30A:1797-1803.
29. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005, 25:4435-4438.
30. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 2002, 9:1017-1029. 10.1016/S1097-2765(02)00522-1, 12049738.